The combination will now join Bristol Myers Squibb’s Opdivo in the list of bladder cancer drugs available on the NHS.

Padcev-Keytruda is now the standard of care (SoC) in first-line mUC treatment due to the positive results of the Phase III EV-302 trial (NCT04223856), which found that the cancer-fighting duo ...

A new treatment regimen for advanced bladder cancer combining MSD's Keytruda with Astellas' Padcev has been given the green ...

The bladder cancer market is projected to reach $16 billion across 8 major markets (8MM) by 2033, driven by new therapies and ...

Three Motley Fool contributors think they've found unstoppable dividend stocks to buy right now. Here's why they picked ...

While this new treatment offers a vital lifeline, experts are simultaneously stressing the critical importance of recognising ...

Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit ...

Excitement is building as a new treatment for advanced bladder cancer that doubles survival time has been approved for NHS ...

"Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since ...